Aeolus Pharmaceuticals Inc. announced unaudited consolidated results for the second quarter and six months ended March 31, 2016. Revenue for the three months ended March 31, 2016 was approximately $565,000, against revenue of $1,189,000 for the three months ended March 31, 2015. The revenue is from the Lung ARS medical countermeasure development contract with BARDA, a division of the U.S. Department of Health and Human Services. Lower revenue in 2016 reflects the timing of the initiation of program items and revenue recognition under accounting rules. Loss from operations was $629,000 against $712,000 a year ago. Net loss attributable to common stockholders was $2,535,000 or $0.02 per diluted share against $712,000 or $0.01 per diluted share a year ago. Revenue for the six months ended March 31, 2016 was approximately $870,000, against revenue of $2,114,000 for the six months ended March 31, 2015. The revenue is from the Lung ARS medical countermeasure development contract with BARDA. Lower revenue in 2016 reflects the timing of the initiation of program items and revenue recognition under accounting rules. Loss from operations was $1,377,000 against $1,410,000 a year ago. Net loss attributable to common stockholders was $4,148,000 or $0.03 per diluted share a year ago against $1,410,000 or $0.01 per diluted share a year ago. a year ago. Net cash used in operating activities was $1,755,000 against $1,269,000 a year ago.